Skip to main content
Clinical Trials/IRCT20150704023055N2
IRCT20150704023055N2
Completed
Phase 2

To evaluate the effectiveness of hemoperfusion in patients with severe coronavirus disease 2019 (COVID-19)

Babol University of Medical Sciences0 sites10 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Babol University of Medical Sciences
Enrollment
10
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with diagnosis of COVID\-19 based on the clinical manifestations, lung CT\-scan, testing of pharyngeal sample using real\-time polymerase chain reaction and the physician´s diagnosis
  • Patients who have partial pressure of oxygen in alveoli (PaO2\) less than 60, even after different methods of oxygen\-therapy
  • Patients who have partial pressure of oxygen in alveoli to the fraction of inspired oxygen (PaO2/FiO2\) less than 200
  • Patients who have partial pressure of carbon dioxide in alveoli (PaCo2\) more than 50; PH less than 7\.35; peripheral capillary oxygen saturation (SpO2\) less than 88%; and no improvement has been achieved despite 48 hours of non\-invasive respiratory therapy

Exclusion Criteria

  • Plasma platelet count less than 30000 per microliter
  • Multiple organ dysfunction

Outcomes

Primary Outcomes

Not specified

Similar Trials